Search
AUTO3
go.drugbank.com/drugs/DB17364InvestigationalIt is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.
NP-6A4
go.drugbank.com/drugs/DB17599ExperimentalNP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]
Cefodizime
go.drugbank.com/drugs/DB13470InvestigationalCefodizime is a third generation cephalosporin with a broad spectrum of antibacterial activity.[A275053, A275058]
Matrix-M
go.drugbank.com/drugs/DB16369InvestigationalMatrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. … [L27981] This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.
PPI-1019
go.drugbank.com/drugs/DB05832InvestigationalApan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Norgestomet
go.drugbank.com/drugs/DB11440InvestigationalVet approvedNorgestomet, also known as 11β-methyl-17-hydroxy-19-norprogesterone acetate, is a steroidal progestin used in veterinary medicine to control estrus and ovulation in cattle.
D-norleucine
go.drugbank.com/drugs/DB04419ExperimentalAn unnatural amino acid that is used experimentally to study protein structure and function. It is structurally similar to METHIONINE, however it does not contain SULFUR.
Synonyms: D-norleucine, D-(−)-norleucinePradofloxacin
go.drugbank.com/drugs/DB11453ExperimentalVet approvedPradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.
EGEN-001
go.drugbank.com/drugs/DB05953InvestigationalEGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity
EU204
go.drugbank.com/drugs/DB17438InvestigationalEU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.